Milton J. Finegold

Milton J. Finegold

Auto-generated profile, based on publicly available information

Milton J. Finegold

Department of Pathology, Baylor College of Medicine

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Scientific Reports
Verified
Journal Article
Open access
RLRong Luo
Rong Luo
SKSherry A. Klumpp
Sherry A. Klumpp
MFMilton J. Finegold
Milton J. Finegold
SMSankar N. Maity
Sankar N. Maity
We previously demonstrated that CBF activity is needed for cell proliferation and early embryonic development. To examine the in vivo function of CBF in differentiated hepatocytes, we conditionally deleted CBF-B in hepatocytes after birth. Deletion of CBF-B resulted in progressive liver injury and severe hepatocellular degeneration 4 weeks after birth. Electron microscopic examination demonstrated pleiotropic changes of hepatocytes including enlarged cell and nuclear size, intracellular lipid deposition, disorganized endoplasmic reticulum, and mitochondrial abnormalities. Gene expression analyses showed that deletion of CBF-B activated expression of specific endoplasmic reticulum (ER) stress-regulated genes. Inactivation of CBF-B also inhibited expression of C/EBP alpha, an important transcription factor controlling various metabolic processes in adult hepatocytes. Altogether, our study reveals for the first time that CBF is a key transcription factor controlling ER function and metabolic processes in mature hepatocytes.

7 December 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ATAngela Trobaugh-Lotrario
Angela Trobaugh-Lotrario
HKHoward M. Katzenstein
Howard M. Katzenstein
SRSarangarajan Ranganathan
Sarangarajan Ranganathan
DLDolores H. Lòpez-Terrada
Dolores H. Lòpez-Terrada
MKMark D. Krailo
Mark D. Krailo
MFMilton J. Finegold
Milton J. Finegold
PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology. PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review. RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74; P = .17), respectively. CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.

1 July 2010 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
RSReka Szigeti
Reka Szigeti
BCBruno Chumpitazi
Bruno Chumpitazi
MFMilton J. Finegold
Milton J. Finegold
SRSarangarajan Ranganathan
Sarangarajan Ranganathan
WCWilliam J. Craigen
William J. Craigen
NTNina Tatevian
Nina Tatevian
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS; OMIM%249210) is a rare and severe form of congenital intestinal and urinary dysfunction and malformation. Histologic studies suggest that the predominant intestinal manifestation is smooth muscle myopathy. Molecular observations have linked the disease to the neuronal nicotinic acetylcholine receptor (ηAChR), namely the absence of a functional α3 subunit of the ηAChR in patients with MMIHS. We describe a case of MMIHS in association with a de novo deletion of the proximal long arm of chromosome 15 (15q11.2). Histologic evaluation revealed an appropriate light microscopic appearance of both the circular and longitudinal layers of the small bowel muscularis propria. Immunohistochemical staining for smooth muscle actin, however, was selectively absent in the circular layer, demonstrating isolated absence in a unique and previously undescribed pattern. These observations raise the possibility that the proximal long arm of chromosome 15 (15q11) may be of clinical significance in MMIHS.

1 October 2012 in Molecular Therapy
Verified
Journal Article
Open access
NPNicole K Paulk
Nicole K Paulk
KWKarsten Wursthorn
Karsten Wursthorn
AHAnnelise Haft
Annelise Haft
CPCarl Pelz
Carl Pelz
GCGregory Clarke
Gregory Clarke
MGMarkus Grompe
Markus Grompe
Genetic fumarylacetoacetate hydrolase (Fah) deficiency is unique in that healthy gene-corrected hepatocytes have a strong growth advantage and can repopulate the diseased liver. Unfortunately, similar positive selection of gene-corrected cells is absent in most inborn errors of liver metabolism and it is difficult to reach the cell replacement index required for therapeutic benefit. Therefore, methods to transiently create a growth advantage for genetically modified hepatocytes in any genetic background would be advantageous. To mimic the selective pressure of Fah deficiency in normal animals, an efficient in vivo small molecule inhibitor of FAH, 4-[(2-carboxyethyl)-hydroxyphosphinyl]-3-oxobutyrate (CEHPOBA) was developed. Microarray analysis demonstrated that pharmacological inhibition of FAH produced highly similar gene expression changes to genetic deficiency. As proof of principle, hepatocytes lacking homogentisic acid dioxygenase (Hgd) and hence resistant to FAH inhibition were transplanted into sex-mismatched wild-type recipients. Time course analyses of 4–6 weeks of CEHPOBA administration after transplantation showed a linear relationship between treatment length and replacement index. Compared to controls, recipients treated with the FAH-inhibitor had 20–100-fold increases in liver repopulation. We conclude that pharmacological inhibition of FAH is a promising approach to in vivo selection of hepatocytes.

1 January 2008 in World Journal of Gastroenterology
Verified
Journal Article
Open access
RHRyan W Himes
Ryan W Himes
IRIsaac Raijman
Isaac Raijman
MFMilton J Finegold
Milton J Finegold
HRHeidi V Russell
Heidi V Russell
DFDouglas S Fishman
Douglas S Fishman
Biliary rhabdomyosarcoma (BRMS) is an uncommon childhood malignancy which has been managed surgically. We present a case of a 3-year-old boy with BRMS, in whom endoscopic retrograde cholangiopancreatography (ERCP) was successfully used both diagnostically and therapeutically, thus obviating the need for surgery and its attendant risks of morbidity and mortality. We conclude that ERCP is an effective alternative to surgery for BRMS in some patients.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Open access
HKHoward M. Katzenstein
Howard M. Katzenstein
Wayne L FurmanWayne L Furman
Wayne L Furman
MMMarcio Malogolowkin
Marcio Malogolowkin
MKMark D. Krailo
Mark D. Krailo
BMBeth Elizabeth (Beth) McCarville
Beth Elizabeth (Beth) McCarville
RMRebecka Meyers
Rebecka Meyers
10516Background: The identification of new therapies for high-risk (HR) hepatoblastoma (HB) is challenging. Children’s Oncology Group Study AHEP0731 included a HR stratum to explore novel agents. We report the response rate to vincristine/irinotecan and the outcome of high-risk HB patients. Methods: Patients with newly diagnosed metastatic HB or those with a serum alpha-fetoprotein (AFP) < 100 ng/ml were eligible. Patients received 2 cycles of vincristine (V) 1.5 mg/m2/day intravenously, on days 1 and 8 and irinotecan (I) 50 mg/m2/day, intravenously, on days 1-5. Patients were defined as responders if they had either a 30% decrease in tumor burden according to RECIST criteria or a 90% (> 1 log10 ) decline in the AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of cisplatin/doxorubicin/5-fluorouracil/vincristine (C5VD). Non-responders were to receive 6 cycles of C5VD alone. Results: Thirty-two patients (median age at diagnosis, 26 months, range: 11-159) were enrolled...